NEW YORK (GenomeWeb News) – Aptiv Solutions today announced a partnership with Cancer Genetics for products and services directed at oncology clinical trials.
The two firms did not specify what products or services will result from the deal, but Aptiv said in a statement that they will provide "biopharmaceutical firms with a better understanding of modes of action of a variety of therapeutics and the role of biomarkers in the oncology drug development process."
"The collaboration will provide customers with the products and services necessary to bring oncology therapeutics to their patients faster and at a reduced cost," the Great Falls, Va.-based firm added.
Financial and other terms of the deal were not disclosed.
Aptiv is a biopharmaceutical and medical device development services organization. Among the services it provides are adaptive trial design, early phase product strategy, regulatory services, pharmacovigilance, "and the operational support of a global clinical research organization," it said.
CGI, based in Rutherford, NJ, provides expertise in disease-specific biomarkers, proprietary molecular testing, and oncology lab services to companies in the early stages of clinical trials.